Selenide-Bridged Redox-Responsive Nanoparticles: A Synergistic Strategy to Overcome p53 Mutation-Mediated Drug Resistance in Gastric Cancer
ACS Nano · 04.08.2026 · 20 (30) · 21263-21280
DOI: 10.1021/acsnano.6c06164 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 21.07.2026. Verfasst von Cuiman Tang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Forest Plant Ecology, Ministry of Education, Northeast Forestry University, Harbin150040, People's Republic of China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Nanoparticles, Tumor Suppressor Protein p53, Drug Resistance, Neoplasm. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Natural Science Foundation of Heilongjiang Province, Heilongjiang Provincial Science and Technology Talents and Innovative Talents.
Abstract (Originalsprache)
Selenium deficiency is linked to gastric cancer, and p53 mutant tumors often acquire chemoresistance. To address this, we designed a camptothecin (CPT) dimeric prodrug with a hybrid −S–Se–S– linker (CPT–S–Se-S-CPT). It self-assembles into uniform nanoparticles (SSeSCPT NPs) with dual redox-responsive release triggered by glutathione and reactive oxygen species. Selenium plays dual synergistic roles: it enhances cellular uptake and pharmacokinetics while reducing systemic toxicity; it also acts as a redox-active center to amplify oxidative stress, activating p38/MAPK and unfolded protein response pathways, thereby inducing p53-independent apoptosis and overcoming drug resistance. In vivo, SSeSCPT NPs prolong plasma half-life, achieve efficient tumor accumulation via the EPR effect, and show potent antitumor activity in p53 mutant gastric cancer models. Surface selenium groups recognize Toll-like receptor 4 (TLR4) overexpressed on tumor cells, promoting clathrin/caveolin-mediated endocytosis and bypassing EPR size limitations. This nanoplatform integrates CPT chemotherapy, selenium intervention, and the p53 mutation background into a single system, establishing a toxicity-controlled, efficacy-enhanced strategy. It also reveals how selenium-based nanomaterials remodel redox homeostasis, bypass p53 deficiency, and reprogram apoptotic networks. This work provides mechanistic insights and translational directions for precision therapy of p53 mutant gastrointestinal malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Forest Plant Ecology, Ministry of Education, Northeast Forestry University, Harbin150040, People's Republic of China.
- Engineering Research Center of Forest Bio-Preparation, Ministry of Education, Northeast Forestry University, Harbin150040, People's Republic of China.
- Heilongjiang Provincial Key Laboratory of the Ecological Utilization of Forestry-Based Active Substances, Harbin150040, People's Republic of China.
- National Engineering Laboratory of Bio Resource Eco Utilization, Harbin150040, People's Republic of China.
- College of Chemistry, Chemical Engineering and Resource Utilization, Northeast Forestry University, Harbin150040, People's Republic of China.
- Aulin College, Northeast Forestry University, Harbin150040, People's Republic of China.
ORCID-Profile: Xiuhua Zhao
Förderung
- Natural Science Foundation of Heilongjiang Province
- Heilongjiang Provincial Science and Technology Talents and Innovative Talents
Zitieren
APA
Tang, C., Wang, Z., Liu, Y., Liu, Z., Zhu, W., & Zhao, X. (2026). Selenide-Bridged Redox-Responsive Nanoparticles: A Synergistic Strategy to Overcome p53 Mutation-Mediated Drug Resistance in Gastric Cancer. ACS Nano, 20(30), 21263-21280. https://doi.org/10.1021/acsnano.6c06164
Vancouver
Tang C, Wang Z, Liu Y, Liu Z, Zhu W, Zhao X. Selenide-Bridged Redox-Responsive Nanoparticles: A Synergistic Strategy to Overcome p53 Mutation-Mediated Drug Resistance in Gastric Cancer. ACS Nano. 2026;20(30):21263-21280. doi:10.1021/acsnano.6c06164
BibTeX
@article{Tang2026,
author = {Tang, Cuiman and Wang, Zhongjuan and Liu, Yankun and Liu, Zhicun and Zhu, Wen and Zhao, Xiuhua},
title = {Selenide-Bridged Redox-Responsive Nanoparticles: A Synergistic Strategy to Overcome p53 Mutation-Mediated Drug Resistance in Gastric Cancer},
journal = {ACS Nano},
year = {2026},
volume = {20},
number = {30},
pages = {21263--21280},
doi = {10.1021/acsnano.6c06164}
}
EUVIMED